Genetically Modified Mesenchymal Stromal/Stem Cells as a Delivery Platform for SE-33, a Cathelicidin LL-37 Analogue: Preclinical Pharmacokinetics and Tissue Distribution in C57BL/6 Mice
The SE-33 peptide expressed by genetically modified WJ-MSCs demonstrated predictable pharmacokinetics and effective biodistribution. These findings, together with the previously established safety profile of WJ-MSC-SE33, support its potential as a promising cell-based therapy for bacterial infections, particularly those associated with antibiotic resistance.
Authors
- Sofya Nikitochkina (ORCID: https://orcid.org/0000-0003-3134-6197)
- Dmitry Kashirskikh (ORCID: https://orcid.org/0000-0002-0748-9238)
- Vagif Ali oglu Gasanov
- Е. A. Vorotelyak (ORCID: https://orcid.org/0000-0001-5405-0212)
- Arthur Anatolievich Lee (ORCID: https://orcid.org/0009-0001-3341-4248)
- И.В. Мухина (ORCID: https://orcid.org/0000-0002-8811-0049)
- Victoria A. Khotina (ORCID: https://orcid.org/0000-0003-2096-3237)
- Daria M. Kuzmina (ORCID: https://orcid.org/0000-0003-3231-4146)
- A. V. Vasiliev (ORCID: https://orcid.org/0000-0003-4886-1750)
Institutions
- Privolzhsky Research Medical University (RU)
- Lomonosov Moscow State University (RU)
- Koltzov Institute of Developmental Biology (RU)
Publication Details
- Journal
- Antibiotics
- Published
- 2025-04-24
- DOI
- https://doi.org/10.3390/antibiotics14050429
- Citations
- 1
- Primary Topic
- Antimicrobial Peptides and Activities
- Type
- article
- Field-Weighted Citation Impact
- 1.18
Funders
- Ministry of Science and Higher Education of the Russian Federation